227 related articles for article (PubMed ID: 28789625)
1. Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study.
Ragonese P; Aridon P; Vazzoler G; Mazzola MA; Lo Re V; Lo Re M; Realmuto S; Alessi S; D'Amelio M; Savettieri G; Salemi G
BMC Neurol; 2017 Aug; 17(1):155. PubMed ID: 28789625
[TBL] [Abstract][Full Text] [Related]
2. Risk of cancer among Finnish multiple sclerosis patients.
Hongell K; Kurki S; Sumelahti ML; Soilu-Hänninen M
Mult Scler Relat Disord; 2019 Oct; 35():221-227. PubMed ID: 31404761
[TBL] [Abstract][Full Text] [Related]
3. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis.
Lebrun C; Debouverie M; Vermersch P; Clavelou P; Rumbach L; de Seze J; Wiertlevski S; Defer G; Gout O; Berthier F; Danzon A
Mult Scler; 2008 Apr; 14(3):399-405. PubMed ID: 18420778
[TBL] [Abstract][Full Text] [Related]
4. No increase in cancer incidence detected after cyclophosphamide in a French cohort of patients with progressive multiple sclerosis.
Le Bouc R; Zéphir H; Majed B; Vérier A; Marcel M; Vermersch P
Mult Scler; 2012 Jan; 18(1):55-63. PubMed ID: 21844065
[TBL] [Abstract][Full Text] [Related]
5. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study.
Confavreux C; Saddier P; Grimaud J; Moreau T; Adeleine P; Aimard G
Neurology; 1996 Jun; 46(6):1607-12. PubMed ID: 8649558
[TBL] [Abstract][Full Text] [Related]
6. Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study.
Buttmann M; Seuffert L; Mäder U; Toyka KV
Neurology; 2016 Jun; 86(23):2203-7. PubMed ID: 27170571
[TBL] [Abstract][Full Text] [Related]
7. Incidence of multiple sclerosis in Bagheria City, Sicily, Italy.
Salemi G; Ragonese P; Aridon P; Scola G; Saporito V; Conte S; Savettieri G
Neurol Sci; 2000 Dec; 21(6):361-5. PubMed ID: 11441573
[TBL] [Abstract][Full Text] [Related]
8. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
9. Cancer risk, disease-modifying therapy, and age in multiple sclerosis: A retrospective population-based cohort study.
Greenfield J; Metz LM; Khakban A; Llorian ER; Michaux KD; Traboulsee A; Oh J; Smyth P; Lynd LD; Bulloch AGM; Williams JVA; Patten SB;
Mult Scler Relat Disord; 2023 Dec; 80():105091. PubMed ID: 37924714
[TBL] [Abstract][Full Text] [Related]
10. Multiple sclerosis and cancer in Norway. A retrospective cohort study.
Midgard R; Glattre E; Grønning M; Riise T; Edland A; Nyland H
Acta Neurol Scand; 1996 Jun; 93(6):411-5. PubMed ID: 8836302
[TBL] [Abstract][Full Text] [Related]
11. Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk.
Gaindh D; Kavak KS; Teter B; Vaughn CB; Cookfair D; Hahn T; Weinstock-Guttman B;
J Neurol Sci; 2016 Nov; 370():13-17. PubMed ID: 27772741
[TBL] [Abstract][Full Text] [Related]
12. Association between disease-modifying therapies for multiple sclerosis and healthcare utilisation on a population level: a retrospective cohort study.
Al-Sakran L; Marrie RA; Blackburn D; Knox K; Evans C
BMJ Open; 2019 Nov; 9(11):e033599. PubMed ID: 31772108
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Reder AT; Centonze D; Naylor ML; Nagpal A; Rajbhandari R; Altincatal A; Kim M; Berdofe A; Radhakrishnan M; Jung E; Sandrock AW; Smirnakis K; Popescu C; de Moor C
CNS Drugs; 2021 Mar; 35(3):317-330. PubMed ID: 33743151
[TBL] [Abstract][Full Text] [Related]
14. Incidence and risk of cancer among multiple sclerosis patients: A matched population-based cohort study.
Bosco-Lévy P; Foch C; Grelaud A; Sabidó M; Lacueille C; Jové J; Boutmy E; Blin P
Eur J Neurol; 2022 Apr; 29(4):1091-1099. PubMed ID: 34936169
[TBL] [Abstract][Full Text] [Related]
15. Multiple sclerosis prevalence and incidence in San Vicente del Raspeig, Spain.
Perez-Carmona N; Gimenez-Martinez J; Borrego-Honrubia C; Sempere AP
Mult Scler Relat Disord; 2019 Aug; 33():78-81. PubMed ID: 31170564
[TBL] [Abstract][Full Text] [Related]
16. Women with female infertility seeking medically assisted reproduction are not at increased risk of developing multiple sclerosis.
Kopp TI; Pinborg A; Glazer CH; Magyari M
Hum Reprod; 2022 May; 37(6):1324-1333. PubMed ID: 35265993
[TBL] [Abstract][Full Text] [Related]
17. Incidence of malignant neoplasms and mortality in people affected by multiple sclerosis in the epoch of disease-modifying treatments: A population-based study on Tuscan residents.
Mariottini A; Forci B; Gualdani E; Romoli M; Repice AM; Barilaro A; Mechi C; Massacesi L; Francesconi P
Mult Scler Relat Disord; 2022 Apr; 60():103679. PubMed ID: 35217486
[TBL] [Abstract][Full Text] [Related]
18. Age-Period-Cohort Modeling of Multiple Sclerosis Incidence Rates in Kuwait: 1980-2014.
Akhtar S; Al-Abkal J; Al-Hashel JY; Alroughani R
Neuroepidemiology; 2017; 49(3-4):152-159. PubMed ID: 29161697
[TBL] [Abstract][Full Text] [Related]
19. Epilepsy and multiple sclerosis in Sicily: a population-based study.
Nicoletti A; Sofia V; Biondi R; Lo Fermo S; Reggio E; Patti F; Reggio A
Epilepsia; 2003 Nov; 44(11):1445-8. PubMed ID: 14636354
[TBL] [Abstract][Full Text] [Related]
20. Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety.
Giovannoni G; Galazka A; Schick R; Leist T; Comi G; Montalban X; Damian D; Dangond F; Cook S
Drug Saf; 2020 Jul; 43(7):635-643. PubMed ID: 32447743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
